Kivizidiale (Timolol, Travoprost)

Timolol reduces the production of aqueous humor by blocking β‑adrenergic receptors in the eye, while travoprost, a prostaglandin F2α analogue, increases uveoscleral outflow of aqueous humor. The dual mechanism results in a net decrease in intra‑ocular pressure.

The specific dosing regimen for Kivizidiale is determined by the prescribing clinician. Typically, one drop is instilled in the affected eye(s) once daily, but the exact dose and frequency should follow the healthcare professional’s instructions.

Safety data for Kivizidiale during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Kivizidiale, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kivizidiale combines a beta‑blocker and a prostaglandin analogue in a single formulation, offering the IOP‑lowering benefits of both classes. Compared with monotherapy agents, the combination can achieve greater pressure reduction, potentially simplifying treatment regimens for patients who need dual‑mechanism therapy.

Kivizidiale eye drops should be stored at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed in its original packaging until use, and discard any solution that appears discolored or contaminated.

Kivizidiale is administered topically to the eye. The usual method is to instill one drop into the prescribed eye(s) using the provided dropper, taking care not to touch the tip of the bottle to the ocular surface or any other object.

Serious adverse events associated with Kivizidiale include severe allergic reactions such as angio‑edema, bronchospasm or worsening asthma, marked bradycardia, systemic hypotension, and rare ocular changes like iris pigmentation or periorbital fat atrophy. Patients should seek immediate medical attention if these occur.

Kivizidiale should be avoided in individuals with known hypersensitivity to timolol, travoprost or any excipients, patients with severe asthma or chronic obstructive pulmonary disease, those with sinus bradycardia or heart block, and persons with narrow‑angle glaucoma.